Clinical Trial Update: Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A pediatric Phase 1/2 study assessed the safety and early activity of weekly nab-paclitaxel in children with recurrent or refractory solid tumors; results compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Dermatofibrosarcoma
• Ewing Sarcoma
• Fibrosarcoma
• Histiocytoma
• Malignant Melanoma
• Melanoma
• Neoplasia
• Neoplasm
• Neuroblastoma
• Osteogenic Sarcoma
• Osteosarcoma Tumor
• Pediatrics Osteosarcoma
• Rhabdomyosarcoma
• Sarcoma Ewing
• Sarcoma Osteogenic
• Sarcoma Soft Tissue
• Sarcoma Spindle Cell
• Sarcomas Epitheliod
• Tumors

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Celgene | Conditions: Neuroblastoma, Rhabdomyosarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-12-27